{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:13:11Z","timestamp":1783689191308,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004409","name":"Minist\u00e8re de l\u2019Enseignement Sup\u00e9rieur, de la Recherche Scientifique et des Technologies de l'Information et de la Communication","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015388","name":"Universit\u00e9 de Tunis El Manar","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.pathol.2024.11.014","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T11:09:19Z","timestamp":1739358559000},"page":"570-578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Can residual proliferative cancer burden predict long-term outcomes following neoadjuvant chemotherapy in breast cancer?"],"prefix":"10.1016","volume":"57","author":[{"given":"Imen","family":"Zawati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousra","family":"Troujette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olfa","family":"Adouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroua","family":"Manai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Nouira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Mekki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Manai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Rahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amor","family":"Gamoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.pathol.2024.11.014_bib1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/1745505716677139","article-title":"Neoadjuvant chemotherapy in breast cancers","volume":"12","author":"Masood","year":"2016","journal-title":"Womens Health (Lond)"},{"issue":"5","key":"10.1016\/j.pathol.2024.11.014_bib2","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1245\/s10434-011-2108-2","article-title":"Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer","volume":"19","author":"Kaufmann","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"9938","key":"10.1016\/j.pathol.2024.11.014_bib3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"29","key":"10.1016\/j.pathol.2024.11.014_bib4","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.2012.45.0940","article-title":"Response-guided neoadjuvant chemotherapy for breast cancer","volume":"31","author":"von Minckwitz","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.pathol.2024.11.014_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.pathol.2024.11.014_bib6","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.pathol.2024.11.014_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"28","key":"10.1016\/j.pathol.2024.11.014_bib8","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.pathol.2024.11.014_bib9","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","article-title":"Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype","volume":"35","author":"Symmans","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.pathol.2024.11.014_bib10","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/annonc\/mdy547","article-title":"Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy","volume":"30","author":"Luen","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2024.11.014_bib11","article-title":"Improved prediction of survival outcomes using residual cancer burden in combination with Ki-67 in breast cancer patients underwent neoadjuvant chemotherapy","volume":"12","author":"Kim","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.pathol.2024.11.014_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919827714","article-title":"Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives","volume":"11","author":"Caparica","year":"2019","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"10.1016\/j.pathol.2024.11.014_bib13","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1002\/1097-0142(20001201)89:11<2145::AID-CNCR1>3.0.CO;2-S","article-title":"Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma","volume":"89","author":"Chang","year":"2000","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.pathol.2024.11.014_bib14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00280-007-0506-8","article-title":"Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin\/docetaxel for locally advanced breast cancer","volume":"61","author":"Lee","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.pathol.2024.11.014_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.2012.43.4134","article-title":"Prognostic significance of progesterone receptor\u2013positive tumor cells within immunohistochemically defined luminal A breast cancer","volume":"31","author":"Prat","year":"2013","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.pathol.2024.11.014_bib16","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1158\/1078-0432.CCR-12-3628","article-title":"Ki67 measured after neoadjuvant chemotherapy for primary breast cancer","volume":"19","author":"von Minckwitz","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.pathol.2024.11.014_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejso.2010.10.009","article-title":"Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer","volume":"37","author":"Tanei","year":"2011","journal-title":"Eur J Surg Oncol"},{"issue":"3\u20134","key":"10.1016\/j.pathol.2024.11.014_bib18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000322189","article-title":"Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis","volume":"79","author":"Miglietta","year":"2010","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.pathol.2024.11.014_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mdu508","article-title":"Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy","volume":"26","author":"Sheri","year":"2015","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.pathol.2024.11.014_bib20","doi-asserted-by":"crossref","first-page":"e1355","DOI":"10.1634\/theoncologist.2020-0201","article-title":"Validation of residual proliferative cancer burden as a predictor of long-term outcome following neoadjuvant chemotherapy in patients with hormone receptor-positive\/human epidermal growth receptor 2-negative breast cancer","volume":"25","author":"Miglietta","year":"2020","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.pathol.2024.11.014_bib21","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.pathol.2024.11.014_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"9","key":"10.1016\/j.pathol.2024.11.014_bib23","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.pathol.2024.11.014_bib24","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.pathol.2024.11.014_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234191","article-title":"Prognostic value of the residual cancer burden index according to breast cancer subtype: validation on a cohort of BC patients treated by neoadjuvant chemotherapy","volume":"15","author":"Hamy","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pathol.2024.11.014_bib26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-017-4303-8","article-title":"Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007\/150012; ACRIN 6657)","volume":"165","author":"Campbell","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.pathol.2024.11.014_bib27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.humpath.2013.09.002","article-title":"Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer","volume":"45","author":"Cockburn","year":"2014","journal-title":"Hum Pathol"},{"issue":"8","key":"10.1016\/j.pathol.2024.11.014_bib28","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.5858\/arpa.2012-0290-OA","article-title":"Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application","volume":"137","author":"Corben","year":"2013","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"10.1016\/j.pathol.2024.11.014_bib29","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/RLU.0000000000000531","article-title":"Value of 18F-FDG PET\/CT for early prediction of pathologic response (by residual cancer burden criteria) of locally advanced breast cancer to neoadjuvant chemotherapy","volume":"39","author":"Lee","year":"2014","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1016\/j.pathol.2024.11.014_bib30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/annonc\/mds493","article-title":"Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients","volume":"24","author":"Romero","year":"2013","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.pathol.2024.11.014_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137885","article-title":"Comparison of pathologic response evaluation systems after anthracycline with\/without taxane-based neoadjuvant chemotherapy among different subtypes of breast cancers","volume":"10","author":"Lee","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pathol.2024.11.014_bib32","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/modpathol.2015.53","article-title":"Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy","volume":"28","author":"Peintinger","year":"2015","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.pathol.2024.11.014_bib33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/his.13054","article-title":"An audit of residual cancer burden reproducibility in a UK context","volume":"70","author":"Naidoo","year":"2017","journal-title":"Histopathology"},{"issue":"22","key":"10.1016\/j.pathol.2024.11.014_bib34","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.pathol.2024.11.014_bib35","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.pathol.2024.11.014_bib36","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1245\/s10434-019-07741-w","article-title":"Validation of residual cancer burden as prognostic factor for breast cancer patients after neoadjuvant therapy","volume":"26","author":"M\u00fcller","year":"2019","journal-title":"Ann Surg Oncol"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302525000637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302525000637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:37:14Z","timestamp":1762216634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302525000637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0031302525000637"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2024.11.014","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can residual proliferative cancer burden predict long-term outcomes following neoadjuvant chemotherapy in breast cancer?","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2024.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}